Increased Procoagulant Activity of Red Blood Cells from Patients with Homozygous Sickle Cell Disease and β-Thalassemia

Summary

It has recently been proved that, in vitro, red blood cells (RBCs) from patients with homozygous β-thalassemia behave as procoagulant cells. The procoagulant activity of β-thalassemia RBCs might be the result of an increased exposure of procoagulant phospholipids (i. e. phosphatidylserine) in the outer leaflet of the membrane. In order to test this hypothesis, we compared the catalytic properties of RBCs of patients with β-thalassemia and homozygous sickle cell disease (SS-RBCs) with that of controls. The catalytic parameters (Km, kcat) of prothrombin activation by factor Xa were determined both in the absence and in the presence of RBCs. The turn-over number (kcat) of the reaction was not modified by normal, SS- or (3-thalassemia RBCs. The Km was lower in the presence of normal RBCs (mean value: 9.1 µM) than in the absence of cells (26 µM). The Km measured in the presence of either SS-RBCs (mean value: 1.6 µM) or β-thalassemia RBCs (mean value: 1.5 pM) was significantly lower compared to normal RBCs (p <0.001). No significant difference was observed between SS-RBCs and p-thalassemia RBCs. Annexin V, a protein with high affinity and specificity for anionic phospholipids, inhibited the procoagulant activity of both SS-RBCs and (3-thalassemia RBCs, in a dose-dependent manner. More than 95% inhibition was achieved at nanomolar concentrations of annexin V. These results indicate that the procoagulant activity of both β-thalassemia RBCs and SS-RBCs may be fully ascribed to an abnormal exposure of phosphatidylserine at the outer surface of the red cells.

• References

• 1 Mehta P. Significance of plasma beta-thromboglobulin values in patients with sickle cell disease. J Pediatr 1980; 97: 941-944
• 2 Francis RB. Platelets, coagulation and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coag Fibrinol 1991; 2: 341-353
• 3 Longenecker GL, Beyers BJ, Mankad VN. Platelet regulatory prostanoids and platelet release products in sickle cell disease. Am J Hematol 1992; 40: 12-19
• 4 Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992; 81: 539-544
• 5 Foulon I, Bachir D, Galacteros F, Maclouf J. Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. Arterios Thromb 1993; 13: 421-426
• 6 Peters M, Plaat BEC, Ten Cate H, Wolters HJ, Weening RS, Brandjes DPM. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994; 71: 169-172
• 7 Logothetis J, Constantoulakis M, Economidou J, Stefanis C, Hakas P, Angoustaki O, Sofraniadou K, Loewenson R, Bilek MS. Thalassemia major (homozygous (3-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology 1972; 22: 294-304
• 8 Sinniah D, Vignaendra V, Kamaruddin A. Neurological complications of (3-thalassemia major. Arch Dis Child 1977; 52: 977-979
• 9 Sonakul D, Pacharee P, Laohapand T, Fucharoen S, Wasi P. Pulmonary artery obstruction in thalassemia. South Asian J Trop Med Pub Hlth 1990; 11: 516-523
• 10 Michaeli J, Mittelman M, Grisaru D, Rachmilewitz EA. Thromboembolic complications in beta thalassemia major. Acta Hematol 1992; 87: 71-74
• 11 Eldor A, Lellouche F, Goldfarb A, Rachmilewitz EA, Maclouf J. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood 1991; 77: 1749-1753
• 12 Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. PADGEM/GMP-140 expression on platelet membranes from homozygous β-thalassemic patients. Br J Haematol 1993; 84: 111-117
• 13 Eldor A, Maclouf J, Goldfarb A, Durst R, Guillin MC, Rachmilewitz EA. A life-long hypercoagulable state in (3-thalassemia major patients. In: Hyper-coagulable States Samama M. ed CRC Press; 1996. in press
• 14 Schroit AJ, Zwaal RFA. Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta 1991; 1071: 313-329
• 15 Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease. Blood 1991; 77: 214-237
• 16 Rachmilewitz EA, Kahane I. The red cell membrane in thalassemia. Br J Haematol 1980; 46: 1-6
• 17 Chiu D, Lubin B, Shohet SB. Erythrocyte membrane lipid reorganization during the sickling process. Br J Haematol 1979; 41: 223-234
• 18 Lubin B, Chiu D, Bastacky J, Roelofsen B, Van Deenen LLM. Abnormalities in membrane phospholipid organization in sickled erythrocytes. J Clin Invest 1981; 67: 1643-1649
• 19 Franck PFH, Chiu DTY, Op Den Kamp JAF, Lubin B, Van Deenen LLM, Roelofsen B. Accelerated transbilayer movement of phosphatidylcholine in sickled erythrocytes. A reversible process. J Biol Chem 1983; 258: 8435-8442
• 20 Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994; 123: 741-748
• 21 Chiu D, Lubin B, Roelofsen B, Van Deenen LLM. Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry. Blood 1981; 58: 398-401
• 22 Middelkoop E, Lubin BH, Bevers EM, Op Den Kamp JAF, Comfurius P, Chiu DTY, Zwaal RFA, Van Deenen LLM, Roelofsen B. Studies on sickled erythrocytes provide evidence that the asymmetric distribution of phosphatidylserine in the red cell membrane is maintained by both ATP-dependent translocation and interaction with membrane skeletal proteins. Biochim Biophys Acta 1988; 937: 281-288
• 23 Borenstein V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 1993; 44: 63-65
• 24 Muller P, Zachowski A, Beuzard Y, Devaux PF. Transmembrane mobility and distribution of phospholipids in the membrane of mouse β-thalassaem-ic red blood cells. Biochim Biophys Acta 1993; 1151: 7-12
• 25 Tait JF, Gibson D. Phospholipid binding of annexin V. Effects of calcium and membrane phosphatidylserine content. Arch Biochem Biophys 1992; 298: 187-191
• 26 Thiagarajan P, Tait JF. Binding of annexin V placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420-17423
• 27 Bezeaud A, Drouet L, Soria C, Guillin MC. Prothrombin Salakta: an abnormal prothrombin characterized by a defect in the active site of thrombin. Thromb Res 1984; 34: 507-518
• 28 Bajaj SP, Rapaport SI, Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Preparative Biochem 1981; 2: 397-412
• 29 Funakoshi T, Heimark RL, Hendrickson LE, Mac Mullen BA, Fujikawa K. Human placental anticoagulant protein: isolation and characterization. Biochemistry 1987; 26: 5572-5578
• 30 Fujikawa K, Legaze ME, Davie EW. Bovine factor X (Stuart Factor): mechanism of activation by a protein from Russell’s viper venom. Biochemistry 1972; 11: 4892-4899
• 31 Hope MJ, Bally MB, Mayer LD, Janoff AS, Cullis RR. Generation of mul-tilamellar and unilamellar phospholipid vesicles. Chem Phys Lipids 1986; 40: 89-107
• 32 Rousser G, Fleischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-496
• 33 Bezeaud A, Denninger MH, Guillin MC. Interaction of human a-thrombin and y-thrombin with antithrombin III, protein C and thrombomodulin. Eur J Biochem 1985; 153: 491-496
• 34 Nesheim ME, Prendergast FG, Mann KG. Interaction of a fluorescent active site directed inhibitor of thrombin: dansylarginine (3-ethyl-1,5-pentane-diyl) amide. Biochemistry 1979; 18: 996-1003
• 35 Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-283
• 36 Van Rijn JLML, Govers-Riemslag JWP, Zwaal RFA, Rosing J. Kinetic studies of prothrombin activation. Effect of factor Va and phospholipids on the formation of the enzyme substrate complex. Biochemistry 1984; 23: 4557-4564
• 37 Yuan J, Kuypers FA, Lewis RA, Fucharoen S, Bunyaratvej A, Schrier SL. Membrane lipid asymmetry in thalassemic red blood cells. Blood 1994; 84: 1021 (abstr)
• 38 Abbott AJ, Nelsestuen GL. Association of a protein with membrane vesicles at the collisional limit: studies with blood coagulation factor Va light chain also suggest major differences between small and large unilamellar vesicles. Biochemistry 1987; 26: 7994-8003
• 39 Fabry ME, Nagel RL. Heterogeneity of red cells in the sickler: a characteristic with practical clinical and pathophysiological implications. Blood Cells 1982; 8: 9-15
• 40 Connor J, Pak CC, Schroit AJ. Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age and clearance by mononuclear cells. J Biol Chem 1994; 269: 2399-2404
• 41 Hermann A, Devaux PF. Alteration of the aminophospholipid translocase activity during in vivo and artificial aging of human erythrocytes. Biochim Biophys Acta 1990; 1027: 41-46